318 related articles for article (PubMed ID: 36400016)
1. Engineered T cell therapy for viral and non-viral epithelial cancers.
Norberg SM; Hinrichs CS
Cancer Cell; 2023 Jan; 41(1):58-69. PubMed ID: 36400016
[TBL] [Abstract][Full Text] [Related]
2. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.
Shafer P; Kelly LM; Hoyos V
Front Immunol; 2022; 13():835762. PubMed ID: 35309357
[TBL] [Abstract][Full Text] [Related]
3. Emerging Strategies in TCR-Engineered T Cells.
Wei F; Cheng XX; Xue JZ; Xue SA
Front Immunol; 2022; 13():850358. PubMed ID: 35432319
[TBL] [Abstract][Full Text] [Related]
4. Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies.
Matsueda S; Chodon T; Koya RC
Adv Exp Med Biol; 2019; 1143():217-229. PubMed ID: 31338822
[TBL] [Abstract][Full Text] [Related]
5. Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies.
Watanabe K; Nishikawa H
Int Immunol; 2021 Oct; 33(11):551-562. PubMed ID: 34374779
[TBL] [Abstract][Full Text] [Related]
6. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Giordano Attianese GMP; Ash S; Irving M
Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
9. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
10. Adoptive T cell therapy: Boosting the immune system to fight cancer.
Leon E; Ranganathan R; Savoldo B
Semin Immunol; 2020 Jun; 49():101437. PubMed ID: 33262066
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
12. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
13. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
[TBL] [Abstract][Full Text] [Related]
14. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
15. Principles of adoptive T cell therapy in cancer.
Met Ö; Jensen KM; Chamberlain CA; Donia M; Svane IM
Semin Immunopathol; 2019 Jan; 41(1):49-58. PubMed ID: 30187086
[TBL] [Abstract][Full Text] [Related]
16. Adoptive cellular therapies: the current landscape.
Rohaan MW; Wilgenhof S; Haanen JBAG
Virchows Arch; 2019 Apr; 474(4):449-461. PubMed ID: 30470934
[TBL] [Abstract][Full Text] [Related]
17. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
18. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
19. Adoptive CD8
Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
